Reviva Pharmaceuticals (RVPH) Expected to Announce Earnings on Wednesday

Reviva Pharmaceuticals (NASDAQ:RVPH) is anticipated to post its Q2 2025 quarterly earnings results before the market opens on Wednesday, August 13th. Analysts expect Reviva Pharmaceuticals to post earnings of ($0.15) per share for the quarter.

Reviva Pharmaceuticals (NASDAQ:RVPH) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.08. On average, analysts expect Reviva Pharmaceuticals to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Reviva Pharmaceuticals Stock Down 5.0%

NASDAQ RVPH opened at $0.41 on Monday. The firm has a market cap of $19.54 million, a PE ratio of -0.52 and a beta of -0.05. The company has a 50 day moving average price of $0.54 and a 200 day moving average price of $0.94. Reviva Pharmaceuticals has a 52 week low of $0.30 and a 52 week high of $4.28.

Institutional Trading of Reviva Pharmaceuticals

An institutional investor recently raised its position in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its position in shares of Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) by 6.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 448,202 shares of the company’s stock after buying an additional 29,063 shares during the period. Geode Capital Management LLC owned 0.93% of Reviva Pharmaceuticals worth $171,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 63.18% of the company’s stock.

Wall Street Analyst Weigh In

Separately, D. Boral Capital reissued a “buy” rating and set a $3.00 target price on shares of Reviva Pharmaceuticals in a research report on Friday, June 27th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Reviva Pharmaceuticals has a consensus rating of “Buy” and an average price target of $9.00.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.